Semaglutide Trial on Weight Trajectories in Grade 3 Obesity Registered

A clinical trial involving semaglutide was registered, with an update dated September 18, 2026. The study, titled "Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity," is listed under identifier NCT07423481. According to the registry, the trial's current status is not yet recruiting. No phase information was provided for this study. The trial aims to examine weight trajectories and predictive factors in patients with grade 3 and complicated obesity who receive semaglutide, based on the study title. No results, outcomes, or efficacy data have been posted for this trial at this time. As the study has not yet begun recruiting participants, no enrollment or interim findings are currently available. Further updates are expected as the trial progresses through its stages, including recruitment and data collection. Readers should note that this brief reflects only the information currently registered for this study and does not represent conclusions about semaglutide's effects in this patient population. For more background on semaglutide, including its approved uses and general information, readers can consult the compound overview.